We have located links that may give you full text access.
The Effectiveness of Ledipasvir/Sofosbuvir in Youth with Genotype 4 Hepatitis C Virus; A Single Egyptian Center Study.
Pediatric Infectious Disease Journal 2018 September 19
BACKGROUND: Licensure of ledipasvir/sofosbuvir for chronic hepatitis C virus (HCV) infection in adolescents, was based upon clinical trials on patients mainly with genotype-1. We aimed to evaluate the effectiveness and short-term safety of this newly approved antiviral in adolescents with HCV genotype-4.
METHOD: This was a study of 51 HCV-infected adolescents, who received the adult dose of ledipasvir/sofosbuvir, once daily for 12 weeks, and were followed-up for 12 weeks post-treatment. Laboratory tests, quantitation of HCV RNA, HCV genotyping, IL-28rs gene polymorphism, and transient elastography were performed at baseline. Follow up visits were done for blood testing and adverse events recording.
RESULTS: The mean age was 14.7+1.5 years (11-17.5), with a male to female ratio of 1.7:1. All patients were genotype 4a, and 76.5% had the CC IL-28 gene polymorphism. About 50% gave a history of HCV-infected mother, and 31% were treatment-experienced. Liver stiffness was F0 in 72.5%, F0-F1 in 13.7%, and F1-F2 in 13.7%. Adverse events were mainly, abdominal pain in 72.5%, headache in 64.7%, and diarrhea in 53% of patients; these were was mild.. A reversible increase in creatinine level with a concomitant decline in eGFR was observed in the first month of treatment. By the end of week 12, a significant decline in liver enzymes was observed. All patients achieved an early, end of treatment, and a sustained virologic response.
CONCLUSION: Adolescent patients with genotype 4 chronic HCV infection, achieved a good response rate with good on-treatment tolerability for ledipasvir/sofosbuvir therapy.
METHOD: This was a study of 51 HCV-infected adolescents, who received the adult dose of ledipasvir/sofosbuvir, once daily for 12 weeks, and were followed-up for 12 weeks post-treatment. Laboratory tests, quantitation of HCV RNA, HCV genotyping, IL-28rs gene polymorphism, and transient elastography were performed at baseline. Follow up visits were done for blood testing and adverse events recording.
RESULTS: The mean age was 14.7+1.5 years (11-17.5), with a male to female ratio of 1.7:1. All patients were genotype 4a, and 76.5% had the CC IL-28 gene polymorphism. About 50% gave a history of HCV-infected mother, and 31% were treatment-experienced. Liver stiffness was F0 in 72.5%, F0-F1 in 13.7%, and F1-F2 in 13.7%. Adverse events were mainly, abdominal pain in 72.5%, headache in 64.7%, and diarrhea in 53% of patients; these were was mild.. A reversible increase in creatinine level with a concomitant decline in eGFR was observed in the first month of treatment. By the end of week 12, a significant decline in liver enzymes was observed. All patients achieved an early, end of treatment, and a sustained virologic response.
CONCLUSION: Adolescent patients with genotype 4 chronic HCV infection, achieved a good response rate with good on-treatment tolerability for ledipasvir/sofosbuvir therapy.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app